Highlights Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Market Closed - Australian S.E. Other stock markets 02:10:43 2024-05-01 am EDT			5-day change	1st Jan Change
0.285 ^AUD	+5.56%		0.00%	-32.94%

Apr. 19	Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program	MT
Feb. 28	Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9%	Feb. 06	MT
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-25	CI
Paradigm Biopharmaceuticals Announces Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification At 6-Month Follow-Up	23-04-11	CI
Paradigm Biopharmaceuticals Limited Announces Injectable PPS Demonstrates Multiple Signals of A DMOAD in PARA_OA_008 Phase 2 Clinical Study	23-04-03	CI
Paradigm Biopharmaceuticals Secures European Ethics Approval for Knee Osteoarthritis Trial	23-03-14	MT
Paradigm Biopharmaceuticals Ltd Receives European Regulatory and Ethics Approval for the Pivotal PARA_OA_002 Global Clinical Trial	23-03-13	CI
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Paradigm Biopharmaceuticals Secures Go-Signal to Advance Phase 3 Osteoarthritis Trial	22-12-28	MT
Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee for the Pivotal Para_OA_002 Clinical Trial	22-12-27	CI
Paradigm Biopharmaceuticals Moves Closer to US Patent Approval for Bone Marrow Treatment	22-12-12	MT
Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium	22-11-10	CI
Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA	22-10-25	CI
Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial	22-10-03	CI
Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial	22-10-03	CI
Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients	22-09-25	CI
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-25	CI
Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases	22-08-07	CI
Paradigm Biopharmaceuticals Limited Partners with NFL Alumni Health for OA Program	22-07-12	CI
Paradigm Biopharmaceuticals Activates UK Site, Secures Canadian Approval for Knee Osteoarthritis Trial	22-07-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Highlights

Filters